Therapeutic Classification: antiretrovirals, antivirals
Pharmacologic Classification: nucleoside reverse transcriptase inhibitors
REMS
Absorption: Well absorbed after oral administration (86% in adults, 66% in infants and children).
Distribution: Distributes into the extravascular space. Some penetration into CSF; remainder of distribution unknown.
Half-Life: 57 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 0.9 hr‡ | 12 hr |
‡On an empty stomach; peak levels occur at 3.2 hr if lamivudine is taken with food. Food does not affect total amount of drug absorbed.
Contraindicated in:
Use Cautiously in:
Derm: alopecia, erythema multiforme, rash, urticaria
Endo: hyperglycemia
F and E: lactic acidosis
GI: anorexia, diarrhea, nausea, vomiting, ↑liver enzymes, abdominal discomfort, dyspepsia, HEPATOMEGALY WITH STEATOSIS, PANCREATITIS ( IN PEDIATRIC PATIENTS)↑ in pediatric patients)
Hemat: anemia, neutropenia, pure red cell aplasia
MS: musculoskeletal pain, arthralgia, muscle weakness, myalgia, rhabdomyolysis
Neuro: fatigue, headache, insomnia, malaise, neuropathy, depression, dizziness, SEIZURES
Resp: cough
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), immune reconstitution syndrome
Drug-drug:
HIV-1 Infection
Renal Impairment
Chronic Hepatitis B
Renal Impairment
Lab Test Considerations:
Mycobacterium avium
infection, cytomegalovirus,Pneumocystis jirovecii
pneumonia, tuberculosis) occur.